Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Authors :: Knudsen, Trine Alma
Hansen, Dennis Lund
Ocias, Lukas Frans
Bjerrum, Ole
Brabrand, Mette
Christensen, Sarah Friis
Eickhardt-Dalbøge, Christina Schjellerup
Ellervik, Christina
El Fassi, Daniel
Frederiksen, Mikael
Kjær, Lasse
Kristensen, Thomas Kielsgaard
Kruse, Torben A.
Larsen, Morten Kranker
Mourits-Andersen, Torben
Möller, Sören
Overgaard, Ulrik Malthe
Severinsen, Marianne Tang
Skov, Vibe
Sørensen, Anders Lindholm
Stentoft, Jesper
Starklint, Jørn
de Stricker, Karin
Thomassen, Mads
Larsen, Thomas S.
Hasselbalch, Hans C.
Source :: Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p746-746, 1p
Publication Year :: 2023
Abstract: Background:Hydroxyurea (HU) is the most commonly used first-line cytoreductive treatment option for patients with myeloproliferative neoplasms (MPN) worldwide. However, increasing evidence on the efficacy and safety of pegylated interferon-alpha2 (IFNα) is emerging, and optimal first-line treatment is to be established.

Full Text Access

Tools